Ruxolitinib

In this video, Raj Chovatiya, MD, PhD, discussed research into the Janus kinase inhibitor ruxolitinib from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.

In this video, Lindsay A.M. Rein, MD, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best available therapy in patients with high-risk polycythemia vera, according to data presented at ASH Annual Meeting.

In this video, John Mascarenhas, MD, discussed the RuxoBEAT study into ruxolitinib treatment in patients with polycythemia vera, which was presented at the ASH Annual Meeting and Exposition.

In this video, John Mascarenhas, MD, discussed the TRANSFORM-1 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.

In this video, John Mascarenhas, MD, discussed the MANIFEST-2 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

ANAHEIM, Calif. — Patients with atopic dermatitis achieved long-term disease control with as-needed use of ruxolitinib cream, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Opzelura achieved significant efficacy for the treatment of atopic dermatitis in children aged as young as 2 years, Incyte announced in a press release.